Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Innoviva Inc
(NQ:
INVA
)
18.86
+0.22 (+1.18%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Innoviva Inc
< Previous
1
2
3
4
Next >
INVA Stock Earnings: Innoviva Misses EPS, Beats Revenue for Q2 2024
July 31, 2024
INVA stock results show that Innoviva missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Innoviva Reports Second Quarter 2024 Financial Results; Highlights Recent Company Progress
July 31, 2024
From
Innoviva, Inc.
Via
Business Wire
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
July 09, 2024
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher.
Via
InvestorPlace
3 Once-in-a-Lifetime Stock Picks Due for an Unprecedented Surge
June 27, 2024
Discover three high-growth stock picks set for unprecedented surges in the metals, marine transportation, and pharmaceutical industries.
Via
InvestorPlace
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
June 18, 2024
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products.
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
May 15, 2023
Via
Benzinga
Innoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 03, 2024
From
Innoviva, Inc.
Via
Business Wire
3 Under-$20 Stocks That Could Make You a Fortune
May 31, 2024
Discover three under-$20 stocks that could make a fortune in the pharmaceuticals, entertainment, and application software industries.
Via
InvestorPlace
INVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024
May 08, 2024
INVA stock results show that Innoviva beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva to Participate in the BofA Securities Health Care Conference
May 08, 2024
From
Innoviva, Inc.
Via
Business Wire
Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
April 24, 2024
From
Innoviva Specialty Therapeutics
Via
Business Wire
5 Value Stocks In The Healthcare Sector
March 04, 2024
Via
Benzinga
Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
February 29, 2024
From
Innoviva, Inc.
Via
Business Wire
If You Can Only Buy One Biotech Stock in January, It Better Be One of These 3 Names
January 10, 2024
Biotech is one of the areas of interest in the market today, adding a biotech stock could be huge play this month.
Via
InvestorPlace
Chart Of The Day: Innoviva - Individual Investor Favorite
January 08, 2024
100% technical buy signals 14 new highs and up 12.87% in the last month 36.40+ Weighted Alpha
Via
Talk Markets
Innoviva Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress
November 01, 2023
From
Innoviva, Inc.
Via
Business Wire
Positive Results Announced in Largest Pivotal Phase 3 Trial of a First-in-Class Oral Antibiotic to Treat Uncomplicated Gonorrhea
November 01, 2023
From
Innoviva Specialty Therapeutics
Via
Business Wire
A Look Into Healthcare Sector Value Stocks
October 02, 2023
Via
Benzinga
Innoviva to Participate in the Cantor Global Healthcare Conference
September 19, 2023
From
Innoviva, Inc.
Via
Business Wire
XACDURO®, The First and Only Antibiotic Developed to Target Acinetobacter, Now Available to Treat Hospital-Acquired Bacterial Pneumonia (HABP) and Ventilator-Associated Bacterial Pneumonia (VABP) in Adults
September 18, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Appoints Stephen Basso as Chief Financial Officer
August 25, 2023
From
Innoviva, Inc.
Via
Business Wire
Innoviva Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
August 02, 2023
From
Innoviva, Inc.
Via
Business Wire
Overview Of Value Stocks In The Healthcare Sector
July 31, 2023
Via
Benzinga
Why These 7 Stocks Are the Best Ways to Play Biotech Right Now
July 11, 2023
With biotech stocks offering myriad viable opportunities irrespective of broader conditions, this sector is worth a closer look.
Via
InvestorPlace
Innoviva to Participate in the Goldman Sachs Annual Global Healthcare Conference
June 06, 2023
From
Innoviva, Inc.
Via
Business Wire
AstraZeneca-Spin Off Entasis Secures FDA Approval For First Pathogen-Targeted Therapy Addressing Acinetobacter
May 24, 2023
Via
Benzinga
Innoviva Specialty Therapeutics Announces FDA Approval for XACDURO® (sulbactam for injection; durlobactam for injection), Co-packaged for Intravenous Use
May 23, 2023
From
Innoviva, Inc.
Via
Business Wire
Over $125M Bet On Occidental Petroleum? Check Out These 4 Stocks Insiders Are Buying
May 16, 2023
Although US stocks closed higher on Monday, there were a few notable insider trades.
Via
Benzinga
Results from Pivotal Phase 3 ATTACK Trial of Investigational Sulbactam-Durlobactam for Treatment of Serious Infections Caused by Acinetobacter Published in The Lancet Infectious Diseases
May 11, 2023
From
Innoviva, Inc.
Via
Business Wire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.